Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -173.21% | 310.59% | -207.58% | 396.56% | 108.94% |
| Total Depreciation and Amortization | -3.76% | -3.85% | 8.87% | 6.56% | -2.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 189.56% | -263.47% | 263.32% | -1,918.99% | -101.55% |
| Change in Net Operating Assets | -166.31% | 348.14% | -232.81% | 76.83% | 120.19% |
| Cash from Operations | -34.45% | 36.39% | 3.78% | -10.32% | 4.59% |
| Capital Expenditure | 34.50% | -44.48% | 30.63% | -32.85% | 19.81% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | 100.00% | 99.17% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -645.69% | 222.11% | -106.47% | 293.83% | 200.81% |
| Cash from Investing | -172.51% | 20.47% | 62.74% | -4,079.31% | 109.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 50.00% | -- | 100.00% | -100.00% | -- |
| Issuance of Common Stock | -12.82% | 14.71% | -19.05% | -2.33% | 10.26% |
| Repurchase of Common Stock | -11,850.00% | 99.28% | 60.16% | -37.68% | -101,800.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1,433.33% | 106.29% | 61.48% | -39.51% | -272.90% |
| Foreign Exchange rate Adjustments | -- | -100.00% | 106.79% | -800.00% | -117.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -117.31% | 405.66% | 117.50% | -554.65% | -57.09% |